Bioactive lipids in hypertension.

Q1 Pharmacology, Toxicology and Pharmaceutics Advances in pharmacology Pub Date : 2023-01-01 Epub Date: 2023-05-10 DOI:10.1016/bs.apha.2023.01.001
John D Imig
{"title":"Bioactive lipids in hypertension.","authors":"John D Imig","doi":"10.1016/bs.apha.2023.01.001","DOIUrl":null,"url":null,"abstract":"<p><p>Hypertension is a major healthcare issue that afflicts one in every three adults worldwide and contributes to cardiovascular diseases, morbidity and mortality. Bioactive lipids contribute importantly to blood pressure regulation via actions on the vasculature, kidney, and inflammation. Vascular actions of bioactive lipids include blood pressure lowering vasodilation and blood pressure elevating vasoconstriction. Increased renin release by bioactive lipids in the kidney is pro-hypertensive whereas anti-hypertensive bioactive lipid actions result in increased sodium excretion. Bioactive lipids have pro-inflammatory and anti-inflammatory actions that increase or decrease reactive oxygen species and impact vascular and kidney function in hypertension. Human studies provide evidence that fatty acid metabolism and bioactive lipids contribute to sodium and blood pressure regulation in hypertension. Genetic changes identified in humans that impact arachidonic acid metabolism have been associated with hypertension. Arachidonic acid cyclooxygenase, lipoxygenase and cytochrome P450 metabolites have pro-hypertensive and anti-hypertensive actions. Omega-3 fish oil fatty acids eicosapentaenoic acid and docosahexaenoic acid are known to be anti-hypertensive and cardiovascular protective. Lastly, emerging fatty acid research areas include blood pressure regulation by isolevuglandins, nitrated fatty acids, and short chain fatty acids. Taken together, bioactive lipids are key contributors to blood pressure regulation and hypertension and their manipulation could decrease cardiovascular disease and associated morbidity and mortality.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"97 ","pages":"1-35"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10918458/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/bs.apha.2023.01.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/5/10 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Hypertension is a major healthcare issue that afflicts one in every three adults worldwide and contributes to cardiovascular diseases, morbidity and mortality. Bioactive lipids contribute importantly to blood pressure regulation via actions on the vasculature, kidney, and inflammation. Vascular actions of bioactive lipids include blood pressure lowering vasodilation and blood pressure elevating vasoconstriction. Increased renin release by bioactive lipids in the kidney is pro-hypertensive whereas anti-hypertensive bioactive lipid actions result in increased sodium excretion. Bioactive lipids have pro-inflammatory and anti-inflammatory actions that increase or decrease reactive oxygen species and impact vascular and kidney function in hypertension. Human studies provide evidence that fatty acid metabolism and bioactive lipids contribute to sodium and blood pressure regulation in hypertension. Genetic changes identified in humans that impact arachidonic acid metabolism have been associated with hypertension. Arachidonic acid cyclooxygenase, lipoxygenase and cytochrome P450 metabolites have pro-hypertensive and anti-hypertensive actions. Omega-3 fish oil fatty acids eicosapentaenoic acid and docosahexaenoic acid are known to be anti-hypertensive and cardiovascular protective. Lastly, emerging fatty acid research areas include blood pressure regulation by isolevuglandins, nitrated fatty acids, and short chain fatty acids. Taken together, bioactive lipids are key contributors to blood pressure regulation and hypertension and their manipulation could decrease cardiovascular disease and associated morbidity and mortality.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
高血压中的生物活性脂质
高血压是一个重大的医疗保健问题,全世界每三个成年人中就有一人患有高血压,并导致心血管疾病、发病率和死亡率。生物活性脂质通过对血管、肾脏和炎症的作用,对血压调节做出了重要贡献。生物活性脂质对血管的作用包括降低血压的血管扩张和升高血压的血管收缩。生物活性脂质在肾脏中释放的肾素增加会促进高血压,而生物活性脂质的抗高血压作用则会增加钠的排泄。生物活性脂质具有促炎和抗炎作用,可增加或减少活性氧,影响高血压患者的血管和肾功能。人体研究证明,脂肪酸代谢和生物活性脂质有助于高血压患者的钠和血压调节。在人类身上发现的影响花生四烯酸代谢的基因变化与高血压有关。花生四烯酸环氧化酶、脂氧合酶和细胞色素 P450 代谢产物具有促高血压和抗高血压作用。欧米伽-3 鱼油脂肪酸二十碳五烯酸和二十二碳六烯酸具有抗高血压和保护心血管的作用。最后,新兴的脂肪酸研究领域包括异降压素、硝化脂肪酸和短链脂肪酸对血压的调节作用。总之,生物活性脂质是调节血压和高血压的关键因素,对它们的控制可以减少心血管疾病及相关的发病率和死亡率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Advances in pharmacology
Advances in pharmacology Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
9.10
自引率
0.00%
发文量
45
期刊最新文献
Drug discovery strategy for TAK-418, a specific inhibitor of LSD1 enzyme activity, as a novel therapy for autism. Evolution of D-amino acid oxidase inhibitors: From concept to clinic. Inhibition of brain glutamate carboxypeptidase II (GCPII) to enhance cognitive function. Modulatory and protective effects of prolyl hydroxylase domain inhibitors in the central nervous system. Neutral sphingomyelinase 2: A promising drug target for CNS disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1